Abstract
Artemisinin is the most rapidly effective drug for Plasmodium falciparum malaria treatment currently in clinical use. Emerging artemisinin-resistant parasites pose a great global health risk. At present, the level of artemisinin resistance is still relatively low with evidence pointing towards a trade-off between artemisinin resistance and fitness loss. Here we show that artemisinin-resistant P. falciparum isolates from Cambodia manifested fitness loss, showing fewer progenies during the intra-erythrocytic developmental cycle. The loss in fitness was exacerbated under the condition of low exogenous amino acid supply. The resistant parasites failed to undergo maturation, whereas their drug-sensitive counterparts were able to complete the erythrocytic cycle under conditions of amino acid deprivation. The artemisinin-resistant phenotype was not stable, and loss of the phenotype was associated with changes in the expression of a putative target, Exp1, a membrane glutathione transferase. Analysis of SNPs in haemoglobin processing genes revealed associations with parasite clearance times, suggesting changes in haemoglobin catabolism may contribute to artemisinin resistance. These findings on fitness and protein homeostasis could provide clues on how to contain emerging artemisinin-resistant parasites.
Similar content being viewed by others
Introduction
Artemisinin and its derivatives have saved millions of malaria patients’ lives by their rapidity of action1. Artemisinin and its derivatives are the only drugs in clinical use that can kill every intra-erythrocytic stage of human malaria parasite Plasmodium falciparum1. Global campaigns have been launched to prevent artemisinin resistance by administering artemisinin only as combination therapies and monitoring artemisinin sensitivity by measuring parasite clearance times at key sentinel sites2. Despite ongoing efforts, P. falciparum infections with delayed parasite clearance following artemisinin treatment began to emerge in Cambodia and, after ten years, have become prevalent throughout the Greater Mekong subregion3,4. Even though the current artemisinin combination therapies (ACTs) can still cure P. falciparum malaria patients, the threat from emerging artemisinin resistance cannot be ignored, particularly since resistance to chloroquine and antifolates both spread from this region to Africa, setting back malaria control and elimination programmes for decades5,6.
Despite unequivocal observations of delayed parasite clearance time in malaria patients, emerging artemisinin resistance presents a unique challenge since reduced drug susceptibility is largely confined to the ring stage with the more mature stages being relatively unaffected7. These parasites are still responsive to artemisinin but less than before3,4,7. Conventional antimalarial sensitivity assays are not capable of differentiating between sensitive and resistant parasites because reduced drug susceptibility is limited to a small period during the early ring stage8,9. Hence, available artemisinin sensitivity assays limit the drug exposure window to early ring parasites, leading to the development of Ring Survival Assay (RSA) and Trophozoite Maturation Inhibition Assay (TMI)9,10. Genetic linkage analysis strongly indicated that a major determinant of delayed parasite clearance by artemisinin is located on chromosome 1311,12. Long-term selection under artemisinin pressure identified a mutation at kelch 13 correlating with reduced artemisinin sensitivity13. The gene is located within the region on chromosome 13 strongly associated with delayed clearance11,12. Transgenic experiments in combination with RSA further supported the role of kelch 13 in artemisinin resistance14,15. However, many parasites with kelch 13 mutations even within the propeller domain, a fan-like structure of the protein, do not present the expected delayed clearance phenotype—and vice versa4. There may be more to artemisinin resistance than only kelch 13 mutations16,17.
Despite being in clinical use in Southeast Asia for approximately two decades, the rise in the level of artemisinin resistance has been relatively slow in comparison to chloroquine resistance and pyrimethamine resistance. It is possible that the orchestrated campaigns to promote artemisinin combination therapy (ACT) and to prevent underdosing have kept artemisinin resistance at a relatively low level. There is also evidence indicating that the development of artemisinin resistance is costly in terms of fitness, which could balance the evolutionary selection drive towards full-blown artemisinin resistance16. Trade-offs between artemisinin resistance and fitness are supported by the observation that prolonged culture of artemisinin-resistant strains without artemisinin exposure leads to reduction in resistance level10. An in vitro selected artemisinin-resistant strain also loses to drug-sensitive counterparts in a growth competition assay18. Understanding the nature of fitness trade-offs in artemisinin resistance could impact the clinical strategy to contain resistant parasites. If these parasites adopt a secondary compensatory mutation to buffer fitness loss, high resistance levels may follow19.
Here, we show that artemisinin-resistant field P. falciparum isolates suffer from fitness loss. The parasites produce fewer progenies. The reduced fitness was exacerbated when the parasites were forced to rely on haemoglobin digestion without extra amino acid supply. The artemisinin resistance phenotype was lost when the drug pressure was removed. Association of single nucleotide polymorphisms at haemoglobin processing genes and shift in clearance time following artemisinin treatment was observed.
Result
Fitness loss in artemisinin-resistant parasites under amino acid starvation
In order to study fitness trade-off, artemisinin-resistant strains (ANL2 and ANL4) from Cambodia were studied in comparison to laboratory strains and drug-sensitive isolates (ANL1 and ANL3) collected during the same period10. The half-life clearance time values following artemisinin treatment of ANL2 (8.55 hours) and ANL4 (8.8 hours) exceed the local median value of 6.1 hours4. They are consistent with the published data showing the higher IC50 values to artesunate of ANL2 (26 nM) and ANL4 (31.25 nM) in comparison to those of ANL1 (half-life of 5.8 hours and IC50 of 8.59 nM) and ANL3 (half-life of 4.6 hours and IC50 of 11.2 nM)10. An initial observation of reduced parasite growth of the resistant parasites during routine culture prompted us to determine whether it is resulted from fewer progenies. Tightly synchronized parasites were cultured, and the number of nuclei per segmented mature schizont was determined by microscopy. Indeed, the distribution curves of the progeny numbers showed a right shift, suggesting that the artemisinin-resistant parasites produced fewer progenies (the average of 21 progenies in sensitive strains as compared to 15 progenies in artemisinin-resistant ANL2 and ANL4 strains) (Fig. 1a–d). The progeny counting observation was confirmed by flow cytometry of the schizont stage parasites stained with SYBR green. The parasites were gated by forward side scatter analysis and determined DNA content by using the FITC-A channel. Fewer ANL4 parasites have the same DNA content in comparison to their artemisinin-sensitive counterpart (Fig. 1b).
To estimate the reduction in the number of mitotic divisions, we simulated cell division process using Monte Carlo algorithm (Fig. 1e). Our simulations employed an algorithm which calculates cell division rate at each time point and accepts cell division events for each cell with a probability proportional to its associated division rate [for detail see Supplementary Materials and Methods]. The simulation indicated that the difference in the number of progenies was consistent with missing approximately one round of mitosis with the average of 5.37 rounds of mitosis in the sensitive parasite and 4.76 rounds in the resistant parasite in each erythrocytic cycle (Fig. 1f). Artemisinin-resistant parasites are known to remain in the ring stage for a longer period than sensitive parasites before maturing into trophozoite, which is consistent with the reduced multiplication and poor fitness in in vitro selected strains20. It is possible that prolonged ring stage, a mechanism proposed to cause artemisinin resistance, could delay the transition toward mitotic division.
Fitness loss is exacerbated under amino acid starvation
Artemisinin interferes with haemoglobin degradation and haemozoin formation by directly targeting released haem and/or inducing oxidative stress21,22. Haem is also instrumental in the activation of artemisinin at the endoperoxide bridge to become parasiticidal against P. falciparum23,24. Since loss of falcipain 2, a key haemoglobin digestive enzyme, has been linked to reduced artemisinin sensitivity, we hypothesized that decrease in haemoglobin processing might make the parasites less vulnerable to artemisinin13,22. However, compromised haemoglobin processing will also potentially reduce fitness, which needs to be compensated by relying more on external sources of amino acids. With this consideration, we put both artemisinin-resistant and -sensitive parasites in low amino acid medium. Loss of fitness in artemisinin-resistant strains was exacerbated in the low amino acid condition (Fig. 2a). The artemisinin-resistant strains failed to mature from ring to trophozoite whereas the sensitive strains did. This maturation failure was not observed when parasites were cultured in the standard complete culture medium. The difference in parasite maturation is presented as maturation ratio between growth in low amino acid condition versus the one in complete medium. A fraction of the resistant parasites showed morphological changes as observed by shrunken cytoplasm (pyknotic form) or extended cytoplasm (fibrillary form) (Fig. 2b).
These phenotypic changes in artemisinin resistance, though subtle, are likely to be facilitated by perturbation in gene expression. Population-wide gene expression analysis revealed small but consistent increase in those of genes encoding unfolded protein responses (UPR) in parasites from patients with delayed parasite clearance following artemisinin treatment25. The hallmark of UPR is the signal from the rough endoplasmic reticulum to the nucleus when protein misfolding is detected. The nucleus then responds by increasing the level of gene expression aimed to salvage imbalanced protein homeostasis in the rough endoplasmic reticulum. Recently, network analysis revealed that Exp1 is a putative target of artemisinin26. Exp1 was shown to be a glutathione transferase and is inhibited by dihydroartemisinin at a nanomolar range26. In addition, in an in vitro-selected parasite line showing reduced artemisinin sensitivity, there were slightly higher levels of exp1 transcript in comparison to that of the parental line26. In further exploration of this issue, we maintained ANL2 in two conditions namely, with and without intermittent artemisinin exposure. ANL2 treated with 52 nM artemisinin exposure once a week had consistently high IC50 (14.31 ng/ml). On the other hand, the IC50 value of ANL2 without any artemisinin exposure for three consecutive months, now denoted ANL2off, fell to that of wild-type 3D7 (2.04 and 3.69 ng/ml, respectively). There was no obvious difference between the levels of kelch 13 and erc (one of the UPR genes) transcripts as determined by quantitative RT-PCR (Fig. 2c). Interestingly, the level of exp1 transcript was lower in ANL2 in comparison to ANL2off especially during the schizont stage (Fig. 2c). The change was observed in every stage especially the schizonts in independent experiments (Fig. 2c).
Association between SNPs at haemoglobin processing genes and parasite clearance time following artemisinin treatment
SNPs from Asian and African parasites were analysed in relation to parasite clearance times following artemisinin treatment. Parasite clearance based on quantitative parasite counts in blood smears of patients receiving artemisinin treatments was measured as the clearance half-life27. A total of 54,061 SNPs covering 14 chromosomes from 667 isolates were used in this study17. We focused on SNPs that are associated with delayed and fast parasite clearance rates. The SNPs that have been strongly associated with delayed parasite clearance are located in ferredoxin, kelch 13, crt, apicoplast ribosomal protein S10 precursor and mdr2 as previously reported [Supplementary Table 1]13,17. We focused on the genes functionally linked to haemoglobin processing genes and found that the SNPs associated with these genes are associated with the change in clearance time especially for the genes encoding peptidase enzymes as shown in Table 1 and depicted in Fig. 3. One of the top SNPs is the V190I mutation at M1-family alanyl aminopeptidase (PfA-M1), listed in the top 98th percentile of variations associated with delayed clearance (p = 1.2 × 10−13). It functions as a broad-spectrum aminopeptidase in the food vacuole that releases amino acid from the N-termini of oligopeptides28,29. Another food vacuole aminopeptidase on the list is dipeptidyl aminopeptidase 1 (DPAP1) (p = 6.0 × 10−13, 97th percentile). Once cleaved, haemoglobin peptides are transported outside the food vacuole, and a group of cytosolic aminopeptidases can digest the peptides further. One of the cytosolic aminopeptidases, M17-family leucyl aminopeptidase (PfLAP), has a V600I mutation that is associated with delayed clearance (p = 6.3 × 10−11, 96th percentile). The SNPs at the genes encoding haemoglobinases of the ANL parasites were previously reported30. These SNPs based on their association scores are not likely to be a causal mutation for artemisinin resistance by themselves, but their presence, as a whole, could be relevant to evolutionary compensation or gain of artemisinin resistance.
When the SNPs associated with fast parasite clearance were analysed, a member of C50 peptidase (PF3D7_0809600) is the first in the list of SNPs associated with fast clearance (Table 1 and Supplementary Table 1). C50 is a large gene family belonging to the cysteine protease clans31. The most well-studied member is separase which controls chromosome segregation by digestively opening the cohesion ring in several species32. The functions of their members are not well defined in malaria parasites33. Many SNPs at the gene encoding P. falciparum C50 cysteine protease (PF3D7_0809600) were found on both delayed-clearance and fast-clearance lists (Table 1 and Supplementary Table 1). A strong association between SNPs at this C50 gene and shift in clearance time indicates that its function might be relevant to artemisinin sensitivity.
Interestingly, the G223R mutation in the gene encoding Plasmepsin III (PM3) was associated with fast artemisinin clearance with the p-value of 5.8 × 10−14 (the 99.9th percentile) (Table 1). This residue is located at the entry of the active site cleft, and the conversion from glycine to arginine is likely to affect substrate accessibility. Copy number variation in pm3 was recently shown to affect piperaquine sensitivity34,35. These observations warrant future studies on epistatic interactions between drug resistant mutations and interplays between selective pressures from different drugs. The emergence of associated SNPs could be the effect of multiple antimalarial drugs in circulation in Cambodia and Thailand. It also does not exclude the important of the SNPs listed in Supplementary Table 1).
Discussion
Fitness loss is a common trade-off during the evolutionary selection of antimicrobial drug resistance because antimicrobial drugs are directed against conserved critical functions. Reduced fitness has been observed in antifolate-resistant and chloroquine-resistant malaria parasites19,36. The evolutionary processes were traced, revealing intricate genetic interactions responsible for eventual full-blown resistance19,36. At present, artemisinin resistance is still emerging and spreading, which should allow preventive measures to be undertaken to thwart development of further resistance or to target the resistance mechanism directly. To date, full blown-resistance to artemisinin antimalarials has not been reported. It is worth noting that the implementation of artemisinin for more than a decade has not led to complete failure of ACT7. The success of artemisinin-based regimens in avoiding treatment failure thus far might reflect intrinsic properties of artemisinin in avoiding resistance.
Robustness plays an important role in drug resistance evolution37. By definition, robustness in evolutionary biology is an ability of the system to withstand mutational changes38,39,40. Fitness loss during the gain of drug-resistant mutations could prevent the evolutionary process to completely overcome drug pressure. Malaria parasites successfully increased robustness during antifolate resistance evolution via amplification of the gene encoding the rate-limiting step enzyme of the folate pathway41,42. Extra pathway flux would compensate for fitness loss during the gain of drug-resistant mutations in the folate enzyme gene downstream in the metabolic pathway19. Even though a well-documented report of artemisinin resistance in western Cambodia was published in 20093, the parasites in Southeast Asia can still be suppressed by artemisinin-based regimens. Nevertheless, cases with longer clearance time by artemisinin have been observed in endemic areas outside western Cambodia7. Failure of parasites to evolutionarily reach full artemisinin resistance could be explained by the fitness loss observed in field isolates in this study and in drug-induced laboratory strains16. This study was performed with the parasite isolates from Cambodia. It is important to perform a similar study with more parasite isolates with reduced artemisinin sensitivity from other geographical regions since artemisinin resistance appears to be the result of convergent evolution with multiple origins16,43. In addition, it is necessary to verify that the loss in fitness observed under amino acid starvation is generally consistent with the rise in artemisinin resistance by expanding the study to include parasites isolates with matching clinical and laboratory phenotypes.
Two possible reasons why robustness in artemisinin resistance evolution cannot yet be achieved might be due to either its multi-target mode of action or its deleterious effect on non-protein targets. Artemisinin derivatives were shown to be cross-linked with multiple proteins in the parasites23,44. Since the action of artemisinin is broad and akin to an imposition of stress, changes via multiple pathways could reduce artemisinin sensitivity16. A matching analogy is reduction of beta-globin in thalassemia. The amount of functional globin is compromised by several mechanisms including mutations affecting globin function, transcription and RNA splicing16. If gain of artemisinin resistance is costly, it will be more advantageous to undergo evolutionary changes via convergent pathways16. The artemisinin resistance phenotype is not stable. Intermittent exposure to the drug is necessary for maintaining the phenotype. This fits well with the temporal nature of gene expression. It is consistent with the population-scale observation on the subtle transcriptomic change in parasites with reduced artemisinin susceptibility25.
Recent findings on mechanisms perturbing artemisinin resistance tend to involve factors controlling protein homeostasis, including UPR, ubiquitination and proteasome25,45,46. It is important to note that haemoglobin digestion might have the role beyond amino acid consumption. For example, haemoglobin digestion was proposed to balance the colloid-osmotic pressure to prevent the lysis of infected red blood cells47. The evolutionary process driving the emergence of artemisinin resistance could be progressively balancing deleterious accumulation of artemisinin-resistant mutations and fine-tuning of protein homeostasis as a fitness compensatory mechanism. The observation of fitness loss under amino acid starvation could be a phenotypic change during the evolutionary process toward fitter and more-resistant parasites which will be catastrophic to human populations living in malaria endemic zones. Efforts to eliminate these evolving parasites and to improve antimalarial development portfolio are urgently needed.
Methods
Malaria parasite culture
P. falciparum parasites were maintained based on a conventional culture method48. The genetic composition of the ANL parasites used in this study was previously described30. Low amino acid medium was prepared using RPMI 1640 Medium w/o Amino Acids, Sodium Phosphate (US Biologies, USA) and 5% freshly-prepared Albumax II (Gibco), supplemented with L-isoleucine (final concentration of 50 mg/L). Schizonts were enriched by using a Percoll gradient49, and ring-stage parasites were subsequently synchronized by sorbitol synchronization50. To test parasite development under amino acid starvation, P. falciparum ring-stage parasites (1% parasitemia) were cultured under low amino acid medium with conventional complete medium as a control. Parasite development was determined after 24 hours and 36 hours by Giemsa staining of standard blood smears. The experiments were performed at least in triplicates.
Flow cytometry was used to estimate the DNA content of mature schizonts51,52,53,54. The parasites in the schizont stage were synchronized by autoMacs Pro Separator (Miltenyl Biotec). The synchronized parasites were fixed with 1% glutaraldehyde in 1X PBS at 4 °C for 1 hour. The parasites were washed with 1X PBS and then stained with 1X SYBR green I in 1X PBS. After 1-hour incubation at room temperature, the parasites were washed twice with 1X PBS and analysed by BD FACSAria II (BD Biosciences). The events were gated by the FSC/SSC profile and by using the FITC channel to deter the signal from SYBR green staining.
Monte Carlo simulation of cell division
The Gompertz’ growth model was used to simulate the number of progenies55. The number of progenies (n) was described by the Gompertz’ equation as follows56
where K is the carrying capacity and r is a constant related to the proliferative ability of the cells. The solution of the Gompertz equation can be written as (see supplementary material for detail derivation)
where n0 = n(t = 0). Assuming that at t = tf, the average number of progenies is nf and n0 = 1, substituting these in equation (2), (see supplementary material for detail derivation)
Using K = 32,tf = 48 hr, and nf = 21 and 15 for drug-sensitive strain and drug-resistant strain, respectively, we obtain rsensitive = 0.044 hr−1 and rresistant = 0.032 hr−1.
Simulation of cell division using Monte Carlo algorithms calculated cell division rate at each time and accepted the cell division event for each cell with a probability proportional to its associated division rate. Cell division process was described by random Poisson statistics57. Each step of the simulation consists of: (1) calculation of the cell division rate at time t, \(R(t)=r\,\mathrm{ln}(K/n(t))\), (2) calculation of the associated cell division probability P(t) = R(t)Δt where Δt is the time step in our simulation which was chosen such that P(t) is much less than one, (3) selection of a random number \(a\in [0,1)\), (4) execution of a cell division event if a < P(t), update number of cell n → n + 1, (5) update generation of each cell gi → gi + 1 where gi is the generation of cell i and (6) update of the simulation time t → t + Δt. Other parameters in the simulations were set as follows: K = 32, n0 = 1, and Δt = 0.1 hour.
Determination of gene expression level
Ring-stage P. falciparum parasites were cultured and enriched twice by 5% sorbitol (Sigma)48,50. Parasites were collected at 0–16, 16–32 and 32–48 hours post invasion (hpi) by centrifugation at 600 × g for 5 minutes. RNA extraction by TRIzol Reagent (ThermoFisher Scientific) was performed according to the manufacture’s protocol. cDNA was generated by reverse transcription with Superscript III First-Strand Synthesis System using random hexamer (ThermoFisher Scientific). Quantitative PCR experiments were performed with specific primers to the genes encoding Plasmepsin II, Kelch 13, ERC and EXP1 using RBC ThermOne Real-Time PCR Premix (RBCBioscience). Real-time PCR analysis was performed using Mastercycler® ep realplex (Eppendorf) at 94 °C for 20 seconds, 60 °C for 30 seconds and 72 °C for 30 (40 cycles). Expression level was normalized as ∆Ct with the genes encoding actin and seryl-tRNA synthetase. Reactions performed without reverse transcriptase were included to monitor genomic DNA contamination.
Genotype-phenotype association analysis
Artemisinin clearance half-life and SNP data were obtained from Tracking Resistance to Artemisinin Collaboration (TRAC) project4,17. Association analyses were performed using PLINK v1.07 (http://pngu.mgh.harvard.edu/purcell/plink/) and FaST-LMM v2.0758,59. For PLINK, p-value were calculated using a linear model. Heterozygous calls were excluded due to the possibility of being the result of mixed infections. Artemisinin clearance half-life was considered as quantitative trait in the analysis. Genetic similarity matrix used in FaST-LMM was calculated from SNP subset that was extracted by PLINK v1.07 using option indep-pairwise 100 10 0.317.
References
White, N. J. Qinghaosu (artemisinin): the price of success. Science 320, 330–334 (2008).
Dondorp, A. M. et al. Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol 8, 272–280, https://doi.org/10.1038/nrmicro2331 (2010).
Dondorp, A. M. et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361, 455–467 (2009).
Ashley, E. A. et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 371, 411–423, https://doi.org/10.1056/NEJMoa1314981 (2014).
Wellems, T. E. & Plowe, C. V. Chloroquine-resistant malaria. J Infect Dis 184, 770–776, https://doi.org/10.1086/322858 (2001).
Naidoo, I. & Roper, C. Mapping ‘partially resistant’, ‘fully resistant’, and ‘super resistant’ malaria. Trends Parasitol 29, 505–515, https://doi.org/10.1016/j.pt.2013.08.002 (2013).
White, N. J. Can new treatment developments combat resistance in malaria? Expert Opin Pharmacother 17, 1303–1307, https://doi.org/10.1080/14656566.2016.1187134 (2016).
Klonis, N. et al. Altered temporal response of malaria parasites determines differential sensitivity to artemisinin. Proc Natl Acad Sci USA 110, 5157–5162, https://doi.org/10.1073/pnas.1217452110 (2013).
Witkowski, B. et al. Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies. Lancet Infect Dis 13, 1043–1049, https://doi.org/10.1016/S1473-3099(13)70252-4 (2013).
Chotivanich, K. et al. Laboratory detection of artemisinin-resistant Plasmodium falciparum. Antimicrob Agents Chemother 58, 3157–3161, https://doi.org/10.1128/AAC.01924-13 (2014).
Cheeseman, I. H. et al. A major genome region underlying artemisinin resistance in malaria. Science 336, 79–82, https://doi.org/10.1126/science.1215966 (2012).
Takala-Harrison, S. et al. Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. Proc Natl Acad Sci USA 110, 240–245, https://doi.org/10.1073/pnas.1211205110 (2013).
Ariey, F. et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 505, 50–55, https://doi.org/10.1038/nature12876 (2014).
Straimer, J. et al. Drug resistance. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science 347, 428–431, https://doi.org/10.1126/science.1260867 (2015).
Ghorbal, M. et al. Genome editing in the human malaria parasite Plasmodium falciparum using the CRISPR-Cas9 system. Nat Biotechnol 32, 819–821, https://doi.org/10.1038/nbt.2925 (2014).
Wilairat, P., Kumpornsin, K. & Chookajorn, T. Plasmodium falciparum malaria: Convergent evolutionary trajectories towards delayed clearance following artemisinin treatment. Med Hypotheses 90, 19–22, https://doi.org/10.1016/j.mehy.2016.02.022 (2016).
Miotto, O. et al. Genetic architecture of artemisinin-resistant Plasmodium falciparum. Nat Genet, https://doi.org/10.1038/ng.3189 (2015).
Hott, A., Tucker, M. S., Casandra, D., Sparks, K. & Kyle, D. E. Fitness of artemisinin-resistant Plasmodium falciparum in vitro. J Antimicrob Chemother, https://doi.org/10.1093/jac/dkv199 (2015).
Kumpornsin, K. et al. Origin of robustness in generating drug-resistant malaria parasites. Mol Biol Evol 31, 1649–1660, https://doi.org/10.1093/molbev/msu140 (2014).
Hott, A. et al. Artemisinin-resistant Plasmodium falciparum parasites exhibit altered patterns of development in infected erythrocytes. Antimicrob Agents Chemother 59, 3156–3167, https://doi.org/10.1128/AAC.00197-15 (2015).
Chugh, M. et al. Protein complex directs hemoglobin-to-hemozoin formation in Plasmodium falciparum. Proc Natl Acad Sci USA 110, 5392–5397, https://doi.org/10.1073/pnas.1218412110 (2013).
Klonis, N. et al. Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake and digestion. Proc Natl Acad Sci USA 108, 11405–11410, https://doi.org/10.1073/pnas.1104063108 (2011).
Wang, J. et al. Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum. Nat Commun 6, 10111, https://doi.org/10.1038/ncomms10111 (2015).
Meshnick, S. R., Taylor, T. E. & Kamchonwongpaisan, S. Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Microbiol Rev 60, 301–315 (1996).
Mok, S. et al. Drug resistance. Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. Science 347, 431–435, https://doi.org/10.1126/science.1260403 (2015).
Lisewski, A. M. et al. Supergenomic Network Compression and the Discovery of EXP1 as a Glutathione Transferase Inhibited by Artesunate. Cell 158, 916–928, https://doi.org/10.1016/j.cell.2014.07.011 (2014).
Flegg, J. A., Guerin, P. J., White, N. J. & Stepniewska, K. Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malar J 10, 339, https://doi.org/10.1186/1475-2875-10-339 (2011).
Poreba, M. et al. Fingerprinting the substrate specificity of M1 and M17 aminopeptidases of human malaria, Plasmodium falciparum. PLoS One 7, e31938, https://doi.org/10.1371/journal.pone.0031938 (2012).
Skinner-Adams, T. S. et al. Plasmodium falciparum neutral aminopeptidases: new targets for anti-malarials. Trends Biochem Sci 35, 53–61, https://doi.org/10.1016/j.tibs.2009.08.004 (2010).
Ponsuwanna, P. et al. Comparative genome-wide analysis and evolutionary history of haemoglobin-processing and haem detoxification enzymes in malarial parasites. Malar J 15, 51, https://doi.org/10.1186/s12936-016-1097-9 (2016).
Cambra, I., Garcia, F. J. & Martinez, M. Clan CD of cysteine peptidases as an example of evolutionary divergences in related protein families across plant clades. Gene 449, 59–69, https://doi.org/10.1016/j.gene.2009.09.003 (2010).
Hirano, T. Chromosome Dynamics during Mitosis. Cold Spring Harb Perspect Biol 7, https://doi.org/10.1101/cshperspect.a015792 (2015).
Mottram, J. C., Helms, M. J., Coombs, G. H. & Sajid, M. Clan CD cysteine peptidases of parasitic protozoa. Trends Parasitol 19, 182–187 (2003).
Amato, R. et al. Genetic markers associated with dihydroartemisinin-piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype-phenotype association study. Lancet Infect Dis 17, 164–173, https://doi.org/10.1016/S1473-3099(16)30409-1 (2017).
Witkowski, B. et al. A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study. Lancet Infect Dis 17, 174–183, https://doi.org/10.1016/S1473-3099(16)30415-7 (2017).
Gabryszewski, S. J., Modchang, C., Musset, L., Chookajorn, T. & Fidock, D. A. Combinatorial Genetic Modeling of pfcrt-Mediated Drug Resistance Evolution in Plasmodium falciparum. Mol Biol Evol 33, 1554–1570, https://doi.org/10.1093/molbev/msw037 (2016).
Chookajorn, T. & Kumpornsin, K. ‘Snakes and Ladders’ of drug resistance evolution. Virulence 2, 244–247 (2011).
Felix, M. A. & Wagner, A. Robustness and evolution: concepts, insights and challenges from a developmental model system. Heredity (Edinb) 100, 132–140, https://doi.org/10.1038/sj.hdy.6800915 (2008).
Masel, J. & Siegal, M. L. Robustness: mechanisms and consequences. Trends Genet 25, 395–403 (2009).
Kitano, H. Biological robustness. Nat Rev Genet 5, 826–837, https://doi.org/10.1038/nrg1471 (2004).
Nair, S. et al. Adaptive copy number evolution in malaria parasites. PLoS Genet 4, e1000243 (2008).
Kidgell, C. et al. A systematic map of genetic variation in Plasmodium falciparum. PLoS Pathog 2, e57 (2006).
Cheeseman, I. H. et al. Pooled sequencing and rare variant association tests for identifying the determinants of emerging drug resistance in malaria parasites. Mol Biol Evol 32, 1080–1090, https://doi.org/10.1093/molbev/msu397 (2015).
Ismail, H. M. et al. Artemisinin activity-based probes identify multiple molecular targets within the asexual stage of the malaria parasites Plasmodium falciparum 3D7. Proc Natl Acad Sci USA 113, 2080–2085, https://doi.org/10.1073/pnas.1600459113 (2016).
Mbengue, A. et al. A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria. Nature 520, 683–687, https://doi.org/10.1038/nature14412 (2015).
Dogovski, C. et al. Targeting the cell stress response of Plasmodium falciparum to overcome artemisinin resistance. PLoS Biol 13, e1002132, https://doi.org/10.1371/journal.pbio.1002132 (2015).
Mauritz, J. M. et al. The homeostasis of Plasmodium falciparum-infected red blood cells. PLoS Comput Biol 5, e1000339, https://doi.org/10.1371/journal.pcbi.1000339 (2009).
Trager, W. & Jensen, J. B. Human malaria parasites in continuous culture. Science 193, 673–675 (1976).
Fernandez, V., Treutiger, C. J., Nash, G. B. & Wahlgren, M. Multiple adhesive phenotypes linked to rosetting binding of erythrocytes in Plasmodium falciparum malaria. Infect Immun 66, 2969–2975 (1998).
Lambros, C. & Vanderberg, J. P. Synchronization of Plasmodium falciparum erythrocytic stages in culture. J Parasitol 65, 418–420 (1979).
Ganter, M. et al. Plasmodium falciparum CRK4 directs continuous rounds of DNA replication during schizogony. Nat Microbiol 2, 17017, https://doi.org/10.1038/nmicrobiol.2017.17 (2017).
Russo, I., Oksman, A., Vaupel, B. & Goldberg, D. E. A calpain unique to alveolates is essential in Plasmodium falciparum and its knockdown reveals an involvement in pre-S-phase development. Proc Natl Acad Sci USA 106, 1554–1559, https://doi.org/10.1073/pnas.0806926106 (2009).
Theron, M., Hesketh, R. L., Subramanian, S. & Rayner, J. C. An adaptable two-color flow cytometric assay to quantitate the invasion of erythrocytes by Plasmodium falciparum parasites. Cytometry A 77, 1067–1074, https://doi.org/10.1002/cyto.a.20972 (2010).
Izumiyama, S., Omura, M., Takasaki, T., Ohmae, H. & Asahi, H. Plasmodium falciparum: development and validation of a measure of intraerythrocytic growth using SYBR Green I in a flow cytometer. Exp Parasitol 121, 144–150, https://doi.org/10.1016/j.exppara.2008.10.008 (2009).
Zwietering, M., Jongenburger, I., Rombouts, F. & Van’t Riet, K. Modeling of the bacterial growth curve. Applied and environmental microbiology 56, 1875–1881 (1990).
Winsor, C. P. The Gompertz curve as a growth curve. Proceedings of the national academy of sciences 18, 1–8 (1932).
Summers, H. D., Wills, J. W., Brown, M. R. & Rees, P. Poisson-event-based analysis of cell proliferation. Cytometry A 87, 385–392, https://doi.org/10.1002/cyto.a.22620 (2015).
Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81, 559–575, https://doi.org/10.1086/519795 (2007).
Lippert, C. et al. FaST linear mixed models for genome-wide association studies. Nat Methods 8, 833–835, https://doi.org/10.1038/nmeth.1681 (2011).
Acknowledgements
The work in the Chookajorn laboratory was supported by Thailand Research Fund-Mahidol University (RSA5880062) and the Faculty of Tropical Medicine, Mahidol University. DB was supported by a scholarship (D43TW006571) from the Fogarty International Center, National Institutes of Health (NIH), USA. LC was supported by grants (U19AI089672 and R01AI128940) from National Institute of Allergy and Infectious Diseases, NIH. TKo was supported by the Royal Golden Jubilee Ph.D. Program (Grant No. PHD/0204/2552).
Author information
Authors and Affiliations
Contributions
P.W. and T.C. designed the study. K.C., N.J.W. and O.M. provided reagents and analysed the data. D.B., N.K., K.K., D.L. and T.K.r. performed experiments. T.K.o. and O.M. conducted bioinformatic analysis. C.M. ran computer modeling. P.W., N.J.W., L.C. and T.C. discussed the data and prepared the manuscript. All authors reviewed the manuscript.
Corresponding author
Ethics declarations
Competing Interests
The authors declare no competing interests.
Additional information
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Bunditvorapoom, D., Kochakarn, T., Kotanan, N. et al. Fitness Loss under Amino Acid Starvation in Artemisinin-Resistant Plasmodium falciparum Isolates from Cambodia. Sci Rep 8, 12622 (2018). https://doi.org/10.1038/s41598-018-30593-5
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-018-30593-5
- Springer Nature Limited